Ketamine’s Role in Spirituality: How One Synthetic Drug Catalyzes a Natural Experience (Woods, 2021) compares the spiritual experiences reported in magic mushroom ingestion, psilocybin research, and the generic medicine currently available worldwide, ketamine.
The Reagan-Udall Foundation for the FDA, in collaboration with the FDA, is hosting a hybrid public workshop on "Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest." Ketamine is a Schedule III controlled substance that is FDA-approved for induction and maintenance of general anesthesia. Although ketamine is not approved for the treatment of conditions such as depression or chronic pain, there has been increased interest in it's use for these types of conditions. This public workshop will explore topics such as the scope of ketamine use, including approved products and compounded products, for these emerging areas of therapeutic interest; potential safety concerns; and online promotion of and access to ketamine.
Speakers will include clinicians, academic researchers, and federal partners. (No psychotherapists or psychedelic therapists are scheduled to speak.)
See also: Neural correlates and subjective experiences in meditation vs psychedelics, including ketamine (Preliminary Lit Review) https://psychedelicmentalhealth.net/neural-correlates-subjective-experiences-meditation-psychedelics-ketamine-psychotherapy/